C9173 — Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
C9173 is a HCPCS Level II code for injection, filgrastim-txid (nypozi), biosimilar, 1 microgram. It belongs to the Outpatient Prospective Payment System section. It was terminated on June 30, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated C9173 on June 30, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9173
- Long descriptor
- Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
- Short descriptor
- Inj, nypozi, 1 mcg
- Added
- January 1, 2025
- Terminated
- June 30, 2025
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9173
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9173 is not quite right, the correct code is very often within a few positions of it.
- C9165Injection, elranatamab-bcmm, 1 mgterminated
- C9166Injection, secukinumab, intravenous, 1 mgterminated
- C9167Injection, adamts13, recombinant-krhn, 10 iuterminated
- C9168Injection, mirikizumab-mrkz, 1 mgterminated
- C9169Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgramterminated
- C9170Injection, tarlatamab-dlle, 1 mgterminated
- C9171Injection, pegulicianine, 1 mgterminated
- C9172Injection, fidanacogene elaparvovec-dzkt, per therapeutic doseterminated
- C9174Injection, datopotamab deruxtecan-dlnk, 1 mgterminated
- C9175Injection, treosulfan, 50 mgterminated
- C9176Tc-99m from domestically produced non-heu mo-99, [minimum 50 percent], full cost recovery add-on, per study dose
- C9248Injection, clevidipine butyrate, 1 mgterminated
- C9250Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 ml
- C9254Injection, lacosamide, 1 mg
- C9257Injection, bevacizumab, 0.25 mg
- C9275Injection, hexaminolevulinate hydrochloride, 100 mg, per study doseterminated
Questions about C9173
What is HCPCS code C9173?
C9173 is a HCPCS Level II code for injection, filgrastim-txid (nypozi), biosimilar, 1 microgram. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9173?
The CMS HCPCS file marks C9173 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9173 still valid?
No. C9173 was terminated on June 30, 2025 and should not be used on new claims.